Please note: Data collection for the registry has been terminated.

The OVARIA registry is a non-interventional post-registration database focused on collection of epidemiological and clinical data of patients with ovarian cancer treated with bevacizumab and olaparib in the Czech Republic. The project was initiated in September 2012 by the Czech Society for Oncology. Obtained data allow for monitoring of CRC patients' treatment and its results. Institute of Biostatistics and Analyses Ltd, a spin-off company of the Masaryk University, provides management and other services to this project.

Primary goals

• Monitoring of total numbers of patients with ovarian cancer in the Czech Republic treated with bevacizumab and olaparib
• Safety evaluation of the drugs monitored
• Effectiveness evaluation of the treatment and therapy regimens used

Secondary goals

• Analysis of patients' survival in relation to clinical factors observed
• Analysis of patients treated with targeted therapy in relation to Czech population-based reference data

Background

The OVARIA registry is a project, which allows for obtaining comprehensive overview of treatment of patients with ovarian cancer in individual stages and its results.

The main goal is monitoring of patients with ovarian cancer treated with bevacizumab and olaparib. Comprehensive and transparent information about overall treatment of the patient, monitoring of therapy sequences and patient's response to the treatment have been collected within the frame of the project.

Besides of patients' epidemiological characteristics, it will also allow for modelling of risk factors for patients' survival and analysis of adverse effects. The registry may also serve for economical purposes and estimations, such as planning of costs for anticancer treatment.